Citigroup Inc. set a CHF 255 price objective on Roche Holding Ltd. (VTX:ROG) in a report issued on Wednesday, October 18th. The firm currently has a neutral rating on the healthcare company’s stock.
Other research analysts also recently issued research reports about the stock. Deutsche Bank AG set a CHF 260 price objective on shares of Roche Holding and gave the stock a neutral rating in a research report on Friday, July 7th. UBS AG set a CHF 260 target price on shares of Roche Holding and gave the stock a neutral rating in a research note on Thursday, July 6th. Goldman Sachs Group, Inc. (The) set a CHF 335 target price on shares of Roche Holding and gave the stock a buy rating in a research note on Thursday, July 20th. J P Morgan Chase & Co reissued a buy rating and set a target price on shares of Roche Holding in a research note on Tuesday, July 11th. Finally, Societe Generale set a CHF 275 target price on shares of Roche Holding and gave the stock a neutral rating in a research note on Thursday, June 29th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of Hold and an average target price of CHF 263.
Shares of Roche Holding (ROG) traded up 0.13% on Wednesday, reaching CHK 230.10. The company’s stock had a trading volume of 1,798,262 shares. Roche Holding has a 12-month low of CHK 218.30 and a 12-month high of CHK 273.00. The company has a market cap of CHK 196.34 billion and a P/E ratio of 20.43. The company’s 50 day moving average price is CHK 243.34 and its 200 day moving average price is CHK 249.92.
COPYRIGHT VIOLATION NOTICE: “Citigroup Inc. Analysts Give Roche Holding Ltd. (ROG) a CHF 255 Price Target” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/10/28/roche-holding-ltd-rog-given-a-chf-255-price-target-at-citigroup-inc.html.
About Roche Holding
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.